Zoetis projects 6%-8% organic revenue growth for 2025 with strong companion animal performance
Q4 2024 Management View CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenue growth of 11% and adjusted net income growth of 15%. U.S. and ...
Zoetis Earnings Top Analysts' Forecasts
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...
Zoetis Inc (ZTS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
Zoetis Inc (ZTS) reports robust financial performance with significant growth in companion animal products and strategic ...
Zoetis Inc. (ZTS) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsSteve Frank - IRKristin Peck - CEOWetteny Joseph ...
Hosted on MSN2d
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
Zoetis, Inc. ZTS delivered fourth-quarter 2024 adjusted earnings (excluding one-time items) of $1.40 per share, which ...
Zoetis Gets Conditional License From USDA for Bird Flu Vaccine
Zoetis said the U.S. Department of Agriculture's Center for Veterinary Biologics issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is ...
Yahoo Finance5d
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?
Zoetis, Inc. ZTS is expected to beat estimates ... tick and heartworm combination product for dogs, Simparica Trio, are expected to have driven revenues in both the United States and International ...